AstraZeneca (LON:AZN)‘s stock had its “sell” rating restated by equities research analysts at UBS Group in a research report issued on Monday, Borsen Zeitung reports. They currently have a GBX 5,400 ($70.56) price objective on the biopharmaceutical company’s stock. UBS Group’s price target would suggest a potential downside of 8.09% from the stock’s current price.
Several other research firms also recently weighed in on AZN. Deutsche Bank reissued a “buy” rating and set a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a report on Monday, February 18th. Bryan, Garnier & Co downgraded AstraZeneca to a “neutral” rating in a report on Friday, February 22nd. Goldman Sachs Group set a GBX 5,000 ($65.33) price objective on AstraZeneca and gave the company a “sell” rating in a report on Tuesday, May 7th. Barclays reissued an “overweight” rating on shares of AstraZeneca in a report on Wednesday, April 10th. Finally, Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a report on Thursday, February 14th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 6,397.70 ($83.60).
Shares of AZN stock traded down GBX 5 ($0.07) during trading hours on Monday, reaching GBX 5,875 ($76.77). The company’s stock had a trading volume of 1,232,891 shares, compared to its average volume of 2,310,000. The company has a market cap of $77.07 billion and a PE ratio of 30.92. AstraZeneca has a fifty-two week low of GBX 5,110 ($66.77) and a fifty-two week high of GBX 6,540 ($85.46). The company has a debt-to-equity ratio of 179.66, a quick ratio of 0.57 and a current ratio of 0.75.
In related news, insider Philip A. J. Broadley bought 520 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was acquired at an average cost of GBX 5,738 ($74.98) per share, with a total value of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer bought 8,500 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were bought at an average cost of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Reverse Stock Split
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.